Neurol. praxi. 2008;9(3):172-175

SUMATRIPTAN FDT - NOVÉ MOžNOSTI PERORÁLNÍ LÉčBY MIGRÉNY

MUDr. Jiří Mastík1, MUDr. Jolana Marková2,3, MUDr. Irena Novotná4, MUDr. Markéta Grünermelová
1 Neurologická klinika LF MU a FN u sv. Anny, Brno
2 Neurologické oddělení Nemocnice Kladno, Regionální poradna pro diagnostiku a léčbu bolesti
3 Neurologická klinika, Fakultní Thomayerova nemocnice, Praha
4 I. neurologická klinika LF MU a FN u sv. Anny Brno

V otevřené klinické studii autoři srovnávali konvenční perorální sumatriptan 50 mg s rychlorozpustnou formou sumatriptanu 50 mg. Na souboru 70 pacientů (66 žen a 4 muži) hodnotili účinek obou léků ve 4 po sobě následujících záchvatech. Hodnotili rychlost nástupu úlevy od bolesti a významné zlepšení bolesti. Dále sledovali nežádoucí účinky a tzv. časnou intervenci. Sumatriptan s rychlou dezintegrací tablety měl rychlejší nástup úlevy od bolesti a byl rovněž účinnější než konvenční sumatriptan. Autoři doporučují novou rychlorozpustnou formu sumatriptanu pro léčbu migrenózních záchvatů, zejména v případě rychlého rozvoje bolesti nebo zvracení.

Keywords: migréna, triptany, sumatriptan, časná intervence, fast desintegrating tablets

Published: July 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mastík J, Marková J, Novotná I, Grünermelová M. SUMATRIPTAN FDT - NOVÉ MOžNOSTI PERORÁLNÍ LÉčBY MIGRÉNY. Neurol. praxi. 2008;9(3):172-175.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache 2000; 40: 792-797. Go to original source... Go to PubMed...
    2. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a metaanalysis of 53 trials. Lancet 2001; 358: 1668-16752. Go to original source... Go to PubMed...
    3. Mastík J, Doležal T. Sumatriptan. Farmakoterapie 2006; 626-630.
    4. Schlopp J, Schellenberg R, Moeckesch B, et al. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephlaalgia 2004; 24: 925-933. Go to original source... Go to PubMed...
    5. Sheftell FD, Dahlof CGH, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain reliéf in the acute treatment of migraine with a fast-desintegrating/rapid release formulation of sumatriptan tablets. Clin Ther 2005; 27(4): 407-417. Go to original source... Go to PubMed...
    6. Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004; 20: 803-809. Go to original source... Go to PubMed...
    7. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687-695. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.